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1. Introduction 
Polysaccharide capsules are structures found on the cell surface of a broad range of bacterial 
species. The polysaccharide capsule often constitutes the outermost layer of the cell, and 
therefore is often involved in mediating direct interactions between the bacteria and its 
environment. It is due to these interactions that polysaccharide capsules have been 
implicated as important virulence factors for many bacterial pathogens. 
Bacterial extracellular polysaccharides (EPS) may be classified as either capsular 
polysaccharides (CPS), where the polysaccharide is intimately associated with the cell 
surface, or as slime polysaccharides, where the polysaccharide is loosely associated with the 
cell [1]. Differentiation between these forms is difficult since CPS may be released from the cell, 
giving the appearance of a slime polysaccharide [1]. In turn, distinguishing between CPS and 
other cell surface polysaccharides, such as O-antigenic moieties of lipopolysaccharide (LPS), 
may also be difficult, since CPS may be found associated with LPS [1].  
Capsular polysaccharides are highly hydrated molecules that are over 95% water [2]. They 
are often linked to the cell surface of the bacterium via covalent attachments to either 
phospholipid or lipid-A molecules, although some CPS may be associated with the cell in 
the absence of a membrane anchor [1, 3]. Capsular polysaccharides can be either homo- or 
heteropolymers composed of repeating monosaccharides joined by glycosidic linkages [4]. 
The multiple hydroxyl groups present within each monosaccharide may be involved in the 
formation of the glycosidic bond, therefore, any two monosaccharides may be joined in a 
number of configurations, which leads to large structural diversity among CPS types. In the 
case of human pathogens, a large number of different capsule serotypes have been 
identified, and certain CPS or K-antigens have been associated with specific infections [4]. 
For example, the Escherichia coli K1 antigen, a homopolymer of α2,8-linked N-
acetylneuraminic acid (NeuNAc), is the major cause of neonatal meningitis [5]. While 
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bacterial species may demonstrate great structural diversity in synthesizing capsules, 
chemically identical capsular polysaccharides may also be synthesized by different bacterial 
species. The Neisseria meningitidis group B capsular polysaccharide is identical to the K1 
polymer of E. coli, and the E. coli K18, K22, and K100 antigens have the same constituents 
and structure as the Haemophilus influenza serotype b capsule [6, 7]. The conservation of CPS 
types between bacterial species raises interesting questions regarding the evolution of 
capsules and the transmission and acquisition of capsule biosynthesis genes [4]. 
The genetic loci necessary for the production of bacterial capsules are primarily clustered at 
a single chromosomal locus, which allows for the coordinate regulation of a large number of 
genes that may be involved in both the biosynthesis and export of capsular polysaccharides 
[4, 1]. In most bacterial species, the capsule gene clusters demonstrate conserved genetic 
organization. The capsules of E. coli have been classified into four groups based on genetic 
organization and biosynthetic criteria and capsules of other bacteria may resemble these 
prototypes. Group 1 capsules include the E. coli K30 capsule and the capsules of Klebsiella sp. 
and Erwinia sp. [8]. Group 2 capsules include the E. coli K1 and K5 capsules, as well as the 
capsules produced by Neisseria sp. and Haemophilus sp. Group 3 capsules include the E. coli 
K10 capsule. Group 4 capsules include the capsules of E. coli K40 and 0111. Both group 2 
and group 3 capsule gene clusters are organized into 3 regions. Regions 1 and 3 are involved 
in the export and modification of the capsular polysaccharides and are conserved between 
members of the group, while region 2 contains the genes responsible for the biosynthesis of 
the capsule and is usually serotype specific [4, 8]. Generally these regions are organized into 
one transcriptional unit and the regions within the capsule locus are divergently transcribed 
[4, 8]. In addition, some genes within a region may be translationally coupled, such as the 
kpsU and kpsC genes in group 2 E. coli capsules, and the kpsM and kpsT genes in group 3 E. 
coli capsules, which allows for balanced expression of two proteins [4]. 
The A+T composition of capsule gene clusters is often significantly higher than the rest of 
the chromosome, suggesting a common ancestry of capsule genes in gram-negative bacteria 
[9]. It is likely that these A+T rich regions have been horizontally transferred between 
bacterial species. In addition, the A+T ratio of region 2 DNA of group 2 E. coli capsule gene 
clusters compared to regions 1 and 3 confirms that capsule diversity has been achieved in 
part through the acquisition of different region 2 sequences [4]. 
The production of a polysaccharide capsule is widespread in pathogenic bacteria. A number 
of functions have been assigned to bacterial capsules including: prevention of dessication, 
adherence, resistance to non-specific host immunity, resistance to specific host immunity, 
and mediating the diffusion of molecules through to the cell surface [4, 1]. 
Capsules may form a hydrated gel around the surface of the bacterial cell, which may 
protect the bacteria from the harmful effects of dessication [10]. This may increase the 
survival of encapsulated bacteria outside of the host, promoting the transmission of 
pathogenic bacteria from one host to another [4]. Mucoid isolates of E. coli, Acinetobacter 
calcoaceticus, and Erwinia stewartii are more resistant to drying than isogenic nonmucoid 
strains [11]. Studies with E. coli have shown that the expression of genes encoding for the 
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colanic acid capsule is increased by dessication [11]. In addition, alginate production by 
Pseudomonas aeruginosa is triggered by high osmolarity, which may be a consequence of 
dessication [12]. 
Capsular polysaccharides may promote adherence of bacteria to both surfaces and other 
bacterial cells, which may facilitate colonization of a particular niche and may lead to the 
formation of biofilms [13]. Cell-surface polysaccharides have been shown to mediate the 
attachment of bacterial cells to one another, leading to biofilm formation and persistence of 
the organisms during colonization [1, 14].  
Capsular polysaccharides are one of the components responsible for resistance to the non-
specific immunity of the host. The presence of a capsule is thought to confer resistance to 
non-specific host defense mechanisms such as complement and complement-mediated 
opsonophagocytosis [4]. Bacterial capsules may resist complement-mediated killing by 
providing a permeability barrier to complement components, which masks the underlying 
cell surface structures that activate complement [15]. The capsule may also act in concert 
with O-antigens to confer resistance to complement-mediated killing [16]. As a result, a 
combination of cell surface structures is responsible for conferring resistance to killing by the 
complement cascade [4]. Finally, capsules are responsible for resistance to complement-
mediated opsonophagocytosis. This resistance may be due to steric effects, which results in the 
capsule acting as a barrier between the C3b deposited on the bacterial surface and the C3b 
receptors present on phagocytes [4]. Alternatively, the resistance to opsonophagocytosis may 
be due to the net negative charge of the polysaccharide capsule [17].  
Capsules may also confer resistance to the specific immune response of the host. Although 
most capsular polysaccharides can elicit an immune response, some capsules are poorly 
immunogenic [4]. Examples of such capsules include those containing NeuNAc, such as the 
E. coli K1 capsule or the capsule of Neisseria meningitidis serogroup B, and the E. coli K5 
capsule, which is similar to desulfoheparin [18, 19]. Because these capsules are structurally 
similar to polysaccharides encountered on host tissue, these capsules are poorly 
immunogenic, and elicit a poor antibody response in the host [20]. 
Burkholderia pseudomallei, the causative agent of melioidosis, is a gram-negative, facultatively 
anaerobic, motile bacillus that is commonly found in the soil and stagnant waters in a 
number of regions around the world, particularly in areas that fall between 20o north and 
20o south of the equator [21, 22]. Infection by B. pseudomallei is often due to either direct 
inoculation into wounds and skin abrasions or to inhalation of contaminated material [22, 
23, 24,]. This would explain the prevalence of the disease among rice farmers as well as 
helicopter pilots in the Vietnam War who developed melioidosis due to inhalation of 
contaminated dust [24]. Melioidosis may present as an acute pneumonia or an acute 
septicemia, which is the most severe form of the disease. The disease may also manifest as a 
chronic infection involving long-lasting suppurative abscesses in numerous sites in the body. 
Infection with B. pseudomallei may even result in a subclinical infection and remain undetected 
for a number of years. Both the chronic and subclinical forms generally remain undiagnosed 
until activated by a traumatic event or a decrease in immunocompetence [25]. B. pseudomallei is 
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inherently resistant to a number of antibiotics, and even with aggressive antibiotic therapy, the 
mortality rate remains high, and the incidence of relapse is common [26, 27]. 
At the time our studies were initiated some cell-associated antigens had been identified and 
characterized in B. pseudomallei. Cell-associated antigens include exopolysaccharide (EPS) 
and lipopolysaccharide (LPS) [28, 29, 30]. The EPS produced by B. pseudomallei was 
determined to be an unbranched polymer of repeating tetrasaccharide units with the 
structure -3)-2-O-acetyl-β-D-Galp-(1-4)-α-D-Galp-(1-3)-β-D-Galp-(1-5)-β-D-KDOp-(2- [31, 32]. 
The role of EPS in virulence was not known, but sera from patients with melioidosis had 
been shown to contain antibodies against EPS [30]. Two other EPS structures were also 
identified; a branched 1,4-linked glucan polymer ((CP-1a) and a triple-branched 
heptasaccharide repeating unit composed of rhamnose, mannose, galactose, glucose, and 
glucuronic acid (CP-2) [33]. The genes involved in the synthesis of these capsules, and the 
role of these capsules in virulence had not been identified. The LPS of B. pseudomallei was 
structurally characterized and reported to contain two types of O-polysaccharide moieties 
termed type I O-PS and type II O-PS [34, 35]. Type II O-PS was found to be an unbranched 
heteropolymer with repeating D-glucose and L-talose residues with the structure -3)-β-D-
glucopyranose-(1-3)-6-deoxy-α-L-talopyranose-(1-. Type II O-PS had been shown to be 
involved in serum resistance [36]. Type II O-PS mutants also demonstrated reduced 
virulence in three animal models of B. pseudomallei infection [36]. Type I O-PS was 
determined to be an unbranched homopolymer with the structure -3)-2-O-acetyl-6-deoxy-β-
D-manno-heptopyranose-(1-, however, the role for this polysaccharide in infection had not 
been defined, nor the genes responsible for its biosynthesis been identified.  
B. thailandensis is a nonpathogenic soil organism originally isolated in Thailand [37]. Based 
on biochemical, immunological, and genetic data, B. pseudomallei and B. thailandensis are 
closely related species. However, these two organisms differ in a number of ways and have 
been classified into two different species [38]. The rRNA sequence of B. thailandensis differs 
from that of B. pseudomallei by 15 nucleotides, and there are significant differences in 
genomic macrorestriction patterns between these organisms [39]. The biochemical profiles of 
these two species differ in that B. thailandensis can utilize L-arabinose whereas B. pseudomallei 
does not [38, 40]. The most distinct difference between these two species, however, is their 
relative virulence. The 50% lethal dose (LD50) for B. pseudomallei in the Syrian hamster model 
of acute melioidosis is <10 organisms, whereas the LD50 for B. thailandensis is approximately 
106 organisms [38]. It has also been shown that the two species can be differentiated based 
on their propensity to cause disease in humans. Environmental strains isolated in Thailand 
that are able to assimilate L-arabinose are not associated with human infection, whereas 
clinical isolates are not able to utilize L-arabinose [41]. 
2. Subtractive hybridization to identify Capsular Polysaccharide 1 (CPS I) 
To identify the genetic determinants that confer enhanced virulence in B. pseudomallei, a 
method combining subtractive hybridization, insertional mutagenesis, and animal virulence 
studies was developed [42]. Subtractive hybridization was carried out between the virulent 
B. pseudomallei and the weakly virulent B. thailandensis in order to isolate DNA sequences 
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encoding for virulence determinants unique to B. pseudomallei. The genomic DNA sample 
from B. pseudomallei containing the sequences of interest was known as the tester DNA, and 
genomic DNA from B. thailandensis, the reference sample, was called the driver DNA. Tester 
and driver DNAs were digested and subjected to two rounds of hybridization. The 
remaining unhybridized sequences were considered tester-specific sequences. To enrich for 
tester-specific sequences, excess driver DNA was added in the hybridizations. The tester-
specific sequences were then amplified by PCR and cloned into the plasmids pPCR or 
pZErO-2.1. Screening of the subtraction library revealed a number of DNA sequences 
unique to B. pseudomallei. Fifteen distinct plasmid inserts from the library were sequenced. 
The DNA inserts ranged from 100 to 800 bp in length and were found to contain an average 
G+C content of approximately 44 to 52%, which is considerably lower than the 68% G+C 
content of the B. pseudomallei chromosome. The DNA sequences were analyzed using the 
NCBI BLASTX program. One of the plasmid inserts, pDD1015, was found to share limited 
homology with WbpX, a glycosyltransferase, from Pseudomonas aeruginosa [43].  
2.1. Demonstration that CPS I is important for the virulence of B. pseudomallei 
The 373-bp DNA insert from pDD1015 was cloned into a mobilizable suicide vector, 
pSKM11 [44]. The resulting plasmid, pSR1015, was mobilized into wildtype B. pseudomallei 
1026b to create the mutant strain SR1015. Since the insert from pDD1015 was found to 
demonstrate homology to a glycosyltransferase from P. aeruginosa, it was postulated that it 
might encode a protein involved in carbohydrate synthesis. Since three carbohydrate 
structures had been previously purified and characterized, antibodies to each of these 
polysaccharides were available. To define the phenotype of SR1015, an ELISA was 
performed with the EPS-specific monoclonal antibody 3015, and B. pseudomallei 1026b and 
SR1015 were both found to contain EPS [45]. SR1015 was also shown to contain type II O-PS 
and to be serum resistant. Immunogold electron microscopy studies using rabbit polyclonal 
sera specific for a type I O-PS–flagellin conjugate was performed on the parent strain, 1026b, 
and SR1015 (Figure 1). B. pseudomallei 1026b reacted with antibodies to both flagellin and 
type I O-PS, as was evident by the distribution of gold particles around the bacterial surface 
and extending out along the flagella (Figure 1A). Unlike B. pseudomallei 1026b, SR1015 
reacted only with the antibodies to flagellin, as the gold particles were found associated only 
with the flagella (Figure 1B). B. thailandensis, the negative control, did not react with the 
antibodies either to flagellin or to type I O-PS (Figure 1C). B. stabilis LMG7000 was also 
shown to react to the antibodies to type I O-PS, indicating this organism may produce a similar 
capsule (Figure 1D). Western blot analysis of proteinase K-digested whole cells from B. 
pseudomallei 1026b, B. thailandensis E264, and B. pseudomallei SR1015 using rabbit polyclonal 
sera raised to O-PS–flagellin protein conjugate confirmed the lack of type I O-PS in SR1015. 
Type I and type II O-PS were stained in B. pseudomallei 1026b, while only type II O-PS was 
stained in the lanes corresponding to B. pseudomallei SR1015 and B. thailandensis. These results 
indicated that we had identified and insertionally inactivated a gene involved in the synthesis 
of the type I O-PS of B. pseudomallei [42]. SR1015 was tested for virulence in the Syrian hamster 
model of acute septicemic melioidosis. The LD50 for SR1015 after 48 h was 3.5 x 105 CFU, while 
the LD50 of the parent strain, 1026b, was <10 CFU. The LD50 for SR1015 was similar to that for 
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the weakly virulent B. thailandensis (6.8 x 105 CFU) [42]. This demonstrated that SR1015 is 
severely attenuated for virulence in this animal model of melioidosis and that type I O-PS is a 
major virulence determinant of B. pseudomallei. We later determined that the type I O-PS was a 
capsular polysaccharide (CPS I), not an O-PS moiety, which will be discussed below. 
 
 
 
Figure 1. Immunogold electron microscopy of B. pseudomallei 1026b (A) and SR1015 (B), B. thailandensis 
E264 (C), and B. stabilis LMG7000 (D). Bacteria were reacted with polyclonal rabbit antiserum directed 
against an O-PS–flagellin protein conjugate absorbed with B. thailandensis E264 to remove the antibodies 
directed against type II O-PS, washed, and reacted with a goat anti-rabbit IgG-gold (5 nm) conjugate. 
Original magnification x330,000. 
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2.2. Cloning and sequencing of the genetic loci required for CPS I production 
and export 
Two methods were used to clone the genes involved in the production and export of type I 
O-PS. The DNA flanking the insertion of pSR1015 was cloned from SR1015 and sequenced. 
We also used transposon mutagenesis to clone the genes involved in production of the 
polysaccharide; this was done to obtain any unlinked genes that may be involved in 
polysaccharide production. Approximately 1,300 transposon mutants were screened for loss 
of type I O-PS by ELISA. Six mutants were identified, and the DNA flanking the transposon 
insertion was cloned and sequenced. The Tn5-OT182 mutants SLR5, SLR8, SLR13, SLR18, 
and SLR19 mapped to the same region of the chromosome. Sequence analysis of the cloned 
fragments revealed the presence of 26 potential open reading frames involved in the 
synthesis and export of type I O-PS [42]. The open reading frames that predicted proteins 
involved in polysaccharide biosynthesis were found to demonstrate homology to proteins 
involved in the synthesis of a polysaccharide structure composed primarily of mannose. The 
other reading frames in the locus predicted proteins involved in the transport of capsular 
polysaccharides in a variety of bacteria, particularly those that produce group 2 and group 3 
capsular polysaccharides [8]. The genes responsible for the production of type I O-PS were 
found to be similar to other loci encoding for capsular polysaccharides in that they are 
divergently transcribed [4]. The gene cluster involved in the production of this 
polysaccharide is also similar to group 3 capsule gene clusters in that there are no genes 
encoding KpsF and KpsU, which are present in group 2 capsule gene clusters [8]. However, 
the organization of the B. pseudomallei type I O-PS gene cluster differs in that it does not 
contain two export regions flanking a single biosynthetic region as seen in other group 3 
capsule polysaccharide clusters [46]. The biosynthetic genes identified are not organized into 
one continuous transcriptional unit; instead, wcbB, manC, and wcbP are separated from the rest 
of the biosynthetic genes. The overall G+C content of this region is about 58%, lower than the 
G+C content of the rest of the chromosome (68%). The low G+C content in these clusters 
suggests that polysaccharide genes have a common origin and may have been transferred 
horizontally between species [9]. The genes involved in the production of this polysaccharide 
were named according to the bacterial polysaccharide gene nomenclature scheme [47]. The 
gene products associated with this cluster are shown in Figure 4. Mutations constructed in a 
number of these genes confirmed their role in the production of this polysaccharide [42]. 
2.3. CPS I was originally identified as a Type I O-polysaccharride moiety 
The polysaccharide with the structure -3)-2-O-acetyl-6-deoxy-β-D-manno-heptopyranose-(1- 
was originally isolated and characterized as an O-PS component of LPS in B. pseudomallei 
and was designated type I O-PS [35]. However, our results suggested that this 
polysaccharide was a capsule rather than an O-PS moiety. The genes involved in the 
production of this capsule demonstrated strong homology to the genes involved in the 
production of capsular polysaccharides in many organisms, including N. meningitidis, H. 
influenzae, and E. coli. In addition, the export genes associated with this cluster are not 
associated with the previously characterized O-PS gene cluster [36]. Western blot analysis of 
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proteinase K cell extracts and silver staining demonstrated that this polysaccharide has a 
high molecular mass (200 kDa) and lacks the banding pattern seen with O-PS moieties. 
Studies by our laboratory indicated that mutants in the production of the core 
oligosaccharide of the LPS are still capable of producing this polysaccharide [48]. Based on 
the above criteria and the genetic similarity to group 3 capsules, we proposed that this 
polysaccharide is a group 3 capsule and designated this capsule CPS I. This conclusion was 
further supported by Isshiki et al who separated this polysaccharide from a smooth 
lipopolysaccharide preparation of B. pseudomallei [49]. 
3. Role of the B. pseudomallei capsule in virulence 
The role of CPS I in the pathogenicity of B. pseudomallei was investigated by performing 
further animal studies, serum bactericidal assays, complement protein C3b deposition 
assays, and radio-labelled phagocytic assays [50]. These experiments were facilitated by 
constructing a deletion strain harbouring a mutation in one of the CPS I genes and by 
complementation of this strain. An in-frame deletion was constructed in wcbB, a gene which 
encodes a glycosyltransferase, resulting in the capsule-minus strain SZ210. To confirm the 
role of wcbB in the biosynthesis of capsule, SZ210 was complemented by the introduction of 
a wild-type copy of the wcbB gene cloned into the mobilizable broad-host-range plasmid 
pBHR1 (MoBiTec). Western blot analysis of proteinase K-digested whole cells was 
performed using mouse monoclonal antibody directed to B. pseudomallei capsule to assess 
capsule production by these strains. Similar to the capsule minus strain SR1015 and B. 
thailandensis E264, which is known to lack this capsule, SZ210 was found to be negative for 
CPS I production, as indicated by the absence of a 200 kDa band that is present for wild-type 
1026b. Complementation of SZ210 by providing the wild type wcbB gene in trans restored 
capsule production. Whole-cell extracts from the complemented strain SZ210(pSZ219) 
reacted to the capsule antibody producing the 200-kDa band corresponding to the B. 
pseudomallei capsule. 
3.1. Production of CPS I correlates with clinical infection 
To establish a correlation between CPS I production and clinical infection a number of 
strains of B. pseudomallei isolated from a variety of clinical specimens were tested for capsule 
production by western blot analysis with polyclonal rabbit antisera to B. pseudomallei CPS I. 
Out of the 55 clinical strains tested for capsule production, 52 were found to produce this 
capsule. Three strains, 420a, 415c, and 375a were found to be negative for capsule 
production, similar to B. thailandensis E264. However, one of the capsule genes, wzt2, was 
successfully amplified from these three strains and following inoculation in the animal 
model, all three of these strains were found to produce capsule by western blot analysis. 
This indicated that CPS I production may be regulated in some strains and its expression 
may be induced in vivo. Therefore all of the 55 clinical strains of B. pseudomallei tested were 
found to produce capsule, establishing a 100% correlation between CPS I production and 
clinical infection [51].  
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3.2. CPS I promotes survival of B. pseudomallei in vivo 
Syrian golden hamsters were inoculated intraperitoneally with 101 to 105 cells of either wild 
type B. pseudomallei 1026b, capsule mutants SR1015 and SZ210, or the complemented strain 
SZ210(pSZ219). One group of animals inoculated with SR1015 also received 100 µg of 
purified B. pseudomallei capsule. After 48 h, the LD50 values were calculated, and the blood of 
the infected animals was diluted and plated for bacterial quantitation. The addition of 
purified capsule significantly increased the virulence of the capsule mutant strain SR1015. 
The LD50 value was calculated to be 34 CFU, similar to the LD50 value of wild-type B. 
pseudomallei 1026b (<10 CFU). In contrast, the LD50 value for SR1015 without the addition of 
purified capsule was calculated to be 3.5 x 105 CFU, 10,000- fold higher than when capsule 
was added to the inoculum. In addition, purified capsule enhanced the survival of SR1015 in 
the blood. Bacteria could not be detected in the blood of hamsters inoculated with SR1015 
alone. However, the number of SR1015 CFU recovered from the blood of infected animals 
was 9.0 x 102 CFU/ml when capsule was added to the inoculum, an almost-1,000-fold 
increase. This number was comparable to the number of wild-type B. pseudomallei 1026b 
bacteria recovered from the blood. The addition of capsule was not toxic to the hamsters, as 
hamsters inoculated with 100 µg of purified capsule alone survived for the duration of the 
experiment without any ill effects. The LD50 value for the capsule mutant strain SZ210 
containing an in frame deletion of the wcbB gene was calculated to be 9.6 x 104 CFU, and the 
number of bacteria in the blood was determined to be 10 CFU/ml. Complementation of this 
strain restored virulence in the animal model, resulting in an LD50 value of 12 CFU, 
comparable to that of wild type B. pseudomallei 1026b. Furthermore, the number of bacteria 
in the blood of animals infected with the complemented strain, SZ210(pSZ219), was 
determined to be 4.9 x 105 CFU/ml, similar to the number of bacteria recovered from animals 
infected with 1026b [50].  
To further demonstrate the role of the capsule in infection by B. pseudomallei, an experiment 
was designed to investigate differences in tissue distribution between the capsule mutant 
strain and the wild type in infected hamsters. Animals were inoculated with 102 CFU of 
either wild-type B. pseudomallei 1026b or the capsule mutant SR1015. At different time 
points, the animals were sacrificed, and the numbers of bacteria in the blood, liver, lungs, 
and spleen of each animal were determined. As seen in Figure 2, the numbers of B. 
pseudomallei 1026b and SR1015 bacteria were nearly undetectable at 12 h (Figure 2A). By 24 
h, the numbers of 1026b bacteria recovered from the blood, lung, liver, and spleen increased, 
while SR1015 was detected only in the spleen (Figure 2B). By 48 h, very high numbers of 
1026b bacteria were recovered from all of the organs taken, representing a dramatic increase 
compared to the inoculum (Figure 2C). In contrast, all of the organs taken from hamsters 
infected with SR1015 contained fewer bacteria (Figure 2C). Of particular interest was the fact 
that the number of SR1015 bacteria recovered from the blood at 48 h was lower than in the 
inoculum, suggesting that the capsule mutant was cleared from the blood more effectively 
than the wild type. The number of SR1015 bacteria recovered from the spleen was higher 
than the number of SR1015 bacteria in the blood, suggesting that SR1015 was being cleared 
from the blood and sequestered in the spleen. The difference in virulence between the two 
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strains can be attributed to capsule production, since the CPS I mutant strain was found to 
have a growth rate similar to that of the wild-type strain 1026b [50]. 
 
Figure 2. Differences in tissue distribution between B. pseudomallei strains 1026b and SR1015 in the 
Syrian hamster model of acute melioidosis. Female Syrian hamsters (three per group) were inoculated 
intraperitoneally with 102 CFU of either strain, and at 12, 24, and 48 h, two groups of animals were 
sacrificed and bacterial quantitation of the tissues was determined. The data represent the average 
number of bacteria found in each tissue and the standard deviation for a given time point. 
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3.3. CPS I production by B. pseudomallei is responsible for persistence in the 
blood by inhibiting complement 
To define the role of the capsule for persistence in the blood, serum bactericidal assays were 
performed with the addition of purified capsule to determine if capsule had an effect on the 
survival of serum-sensitive strains of B. pseudomallei. For these experiments, we utilized a 
double mutant that we constructed in the laboratory, SLR5, which lacks both capsule and O-
polysaccharide, since the capsule mutant SR1015 was previously found to be serum resistant 
[42]. The survival of SLR5 was extremely poor when incubated in the presence of 30% normal 
human serum (NHS). However, the addition of purified capsule increased the survival of 
SLR5 in NHS. The addition of 50 µg of capsule to the reaction increased the numbers of SLR5 
to 5.9 x 101 CFU/ml, and the addition of 100 µg of capsule increased the survival of SLR5 by 
nearly 1,000-fold to 1.9 x 103 CFU/ml. Furthermore, pre-incubation of 30% NHS with 100 µg of 
capsule (PI-CPS) before the addition of bacteria increased the survival of SLR5 100,000-fold to 
4.4 x 106 CFU/ml. This was similar to the survival of SLR5 when incubated with serum that 
was heat-inactivated (HI-NHS). These effects were found to be specific to capsule, since the 
addition of 50 or 100 µg of purified B. pseudomallei O-PS or preincubation of the serum with O-
PS did not increase the survival of serum-sensitive SLR5 [50]. 
Since capsule mutants of B. pseudomallei are serum resistant in that they are not susceptible 
to lysis by the membrane attack complex (MAC) because they still produce O-PS, we 
postulated that the ability of the capsule to enhance survival in the blood could be due to its 
ability to inhibit C3b deposition and opsonization. To investigate the effect of capsule on 
C3b deposition, the amount of C3b deposited on the surfaces of wild-type B. pseudomallei 
1026b and the capsule mutant, SR1015, in the presence of serum was determined by Western 
blot analysis using a mouse monoclonal antibody specific to human complement factor C3b. 
The deposition of C3b was found to be more pronounced in the capsule mutant SR1015 than 
in the wild type in both 10 and 30% NHS. Similar results were observed with the capsule 
mutant SZ210, a strain containing an in-frame deletion of the wcbB gene. More C3b was 
detected when SZ210 was incubated in both 10 and 30% NHS than with 1026b. Optical 
densitometry measurements were performed in order to quantitate the difference in C3b 
deposition between the strains. The average amount of C3b deposited on the surfaces of 
SR1015 and SZ210 bacteria was 3.5-fold higher than for 1026b in 10% NHS and 2.5-fold 
higher in 30% NHS. In addition, there was a shift in the molecular mass of C3b, which 
normally runs at 185 kDa, indicating a covalent attachment of the molecule to the bacterial 
surface. The nature of this attachment was not investigated; however, C3b is thought to 
covalently attach to the bacterial surface through an ester or amide linkage [50, 52]. 
Immunofluorescence microscopy analysis was also performed to demonstrate the difference 
in C3b deposition between the capsule mutant and the wild type. The same experiment 
described above was performed, and samples were reacted with the mouse monoclonal 
antibody to human complement factor C3b, except that the samples were reacted with a 
secondary antibody conjugated to Cy3 and stained with DAPI for visualization of bacterial 
cells. As shown in Figure 3, the B. pseudomallei capsule mutant SR1015 demonstrated more 
reactivity to the antibody to human C3b in the presence of serum than the wild-type 1026b. 
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This is evident from the red fluorescence that corresponds to the C3b bound to the bacterial 
surface surrounding the blue DAPI-stained cells seen when the capsule mutant was 
incubated in the presence of 10% NHS (Figure 3D to F). In contrast, the amount of red 
fluorescence surrounding the DAPI-stained wild-type cells was minimal in the presence of 
10% NHS (Figure 3A to C). There was a dramatic difference in the amount of C3b deposited 
on the surface of the capsule mutant compared to the wild type, which was detectable after 
only 15 min of incubation of the bacteria with human serum (Figure 3B and E). By 60 min, 
there was some C3b deposition on wild-type B. pseudomallei; however, there was still more 
C3b deposited on the surface of the capsule mutant (Figure 3C and F) [50]. This experiment 
was not performed with 30% NHS due to excessive clumping of the samples during the 
fixation process, which resulted in inconsistent and poor staining of the cells. Western blot 
analysis was also performed to determine the amount of complement factor C3b deposition 
on the surface of B. thailandensis E264, a related nonpathogenic organism. The amount of 
C3b deposition in B. thailandensis E264 was more pronounced than with B. pseudomallei 
1026b and was similar to the amount of C3b deposited on the surface of the capsule mutant, 
B. pseudomallei SR1015, in the presence of human serum. The amount of C3b deposition that 
occurred on the surface of B. thailandensis was expected, since the organism is known to lack 
this capsule [42, 50]. 
 
Figure 3. Immunofluorescence microscopy analysis of decreased complement factor C3b deposition in 
10% normal human serum by B. pseudomallei capsule. B. pseudomallei 1026b and SR1015 were incubated 
in 10% normal human serum (NHS), reacted with a mouse monoclonal antibody to human complement 
factor C3b, reacted with a rabbit anti-mouse IgG conjugated to Cy3 (Jackson Laboratories), and stained 
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with DAPI for visualization of whole bacterial cells (Sigma). (A) B. pseudomallei 1026b incubated in PBS; 
(B) 1026b incubated in 10% NHS for 15 min; (C) 1026b incubated in 10% NHS for 60 min; (D) B. 
pseudomallei SR1015 incubated in PBS; (E) SR1015 incubated in 10% NHS for 15 min; (F) SR1015 
incubated in 10% NHS for 60 min. The blue fluorescence indicates the DAPI stained bacteria, and the 
red fluorescence indicates the binding of complement factor C3b to the bacterial surface. 
3.4. The B. pseudomallei capsule CPS I reduces phagocytosis 
The capsule mutant SR1015 was phagocytosed more significantly by PMNL than the wild-
type strain. The proportion of wild-type B. pseudomallei 1026b phagocytosed in the presence 
of 10% NHS was 35.9%, while the proportion of the capsule mutant SR1015 phagocytosed 
was 51.7% (P < 0.001). When each strain was incubated in the presence of 30% NHS, 59.3% 
of the wild-type strain 1026b was phagocytosed by the PMNL after 30 min compared to 
82.3% for the capsule mutant (P < 0.001) [50]. 
3.5. B. pseudomallei CPS I expression is elevated in the presence of 30% normal 
human serum 
The lux reporter strain B. pseudomallei SZ211 was constructed by cloning an internal 
fragment of the wcbB gene into pGSV3-lux, a suicide vector containing the lux operon from 
Photorhabdus luminescens [53]. Absorbance (OD540) and luminescence (in relative light units) 
measurements were taken every 2 h. Capsule expression was higher in the presence of M9 
plus 1% glucose plus 30% normal human serum (NHS) and M9 plus 1% glucose plus 30% 
heat-inactivated serum (HI-NHS) than in M9 plus 1% glucose alone. The increase in light 
production of SZ211 in the presence of serum supports the requirement for capsule for 
survival in serum. The strain B. pseudomallei SZ213 was constructed by cloning an internal 
region of the wbiA gene, which encodes an O-acetyltransferase required for O-acetylation of 
the O-PS component of B. pseudomallei LPS [36]. Light production of this strain was 
measured under the same conditions to determine whether LPS expression was induced in 
the presence of serum. Similar to the capsule, LPS expression was elevated in the presence of 
both 30% NHS and 30% HI-NHS. The levels of expression of both capsule and LPS were not 
significantly different in NHS and HI-NHS, suggesting that the environment of the serum 
may be required for induction of gene expression rather than complement [50]. 
4. Other capsules produced by B.pseudomallei 
Sequence analysis of the completed genome of B. pseudomallei revealed four operons with 
the predicted function of capsular polysaccharide biosynthesis and export [54]. One of these 
operons, with the gene identifiers BPSL2786-2810, corresponds to the previously 
characterized mannoheptose capsule designated CPS I [42, 50]. Three other operons were 
identified. These three capsule operons in the genome of B. pseudomallei were further 
analyzed using the BLAST program and Artemis. The operons are illustrated in Figure 4. 
The operon consisting of the genes BPSS0417-0429, was designated CPS II (Figure 4B). 
Another operon, BPSS1825-1835, was designated CPS III and the predicted homologues 
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were investigated further (Figure 4C). A fourth operon, CPS IV, was found to contain genes 
that may be involved in the synthesis of a capsule with the gene identifiers BPSL2769-2785 
(Figure 4D) [54, 55]. 
 
Figure 4. Organization of the chromosomal regions containing the genes comprising the B. pseudomallei 
capsule operons. The direction of transcription is represented by arrows, and the gene names 
demonstrating the highest degree of homology to the B. pseudomallei open reading frames are indicated. 
The relative sizes of each locus are indicated. (A) B. pseudomallei capsule cluster I (CPS I). (B) B. 
pseudomallei capsule cluster II (CPS II). (C) B. pseudomallei capsule cluster III (CPS III). (D) B. pseudomallei 
capsule cluster IV (CPS IV).  
4.1. Distribution of capsule loci between three Burkholderia species 
Comparative analysis of the genomes of three Burkholderia species, B. pseudomallei, B. mallei 
and B. thailandensis, was performed to determine whether all of the predicted B. pseudomallei 
capsule operons were present in B. mallei and B. thailandensis as well. CPS II, III, and IV were 
found to be present in B. pseudomallei and B. thailandensis, but not B. mallei. This is in contrast 
to CPS I, which is present in B. pseudomallei and B. mallei, but not B. thailandensis [42, 50, 54, 
55, 56, 57]. CPS II was found to be identical between B. pseudomallei and B. thailandensis, but 
B. thailandensis was found to contain two flanking hypothetical genes not present in B. 
pseudomallei. The CPS II genes were found to be deleted entirely from B. mallei. A large 
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chromosomal region ranging from open reading frames BPSS0404 to BPSS0491 including 
CPS II was shown to be deleted in B. mallei compared to B. pseudomallei and replaced with a 
large chromosomal region containing open reading frames BMAA0555 (IS407A orfB) to 
BMAA1784, a unique hypothetical protein not found in B. pseudomallei. The two genomes 
align with the presence of the alkyl hydroperoxidase reductase genes ahpC and ahpF, but 
these are organized in the opposite orientation in B. mallei compared to B. pseudomallei. The 
entire CPS III operon and flanking genes were shown to be the same in both B. pseudomallei 
and B. thailandensis. In contrast, the majority of the CPS III cluster was deleted from B. mallei 
with the exception of the wcaJ and manC genes, as well as the two flanking hypothetical 
genes on one side, and another hypothetical gene on the other side of the deleted region. 
The deletion of the CPS III genes in B. mallei was found to be replaced with the IS407A orfA 
and orfB genes. The entire CPS IV region was found to be replaced in B. mallei and flanked 
by two IS407A elements. The open reading frame BPSL2785, which encodes a hypothetical 
protein, is present in B. mallei (BMA2284.1) ATCC 23344 as well as a number of other B. 
mallei strains, but is organized in the opposite orientation. The genomes of B. pseudomallei, B. 
thailandensis, and B. mallei all diverge upstream of the CPS IV region, but all three organisms 
were found to align at the location of the ompA and hypothetical genes [55]. 
4.2. CPS III does not contribute to the virulence of B. pseudomallei 
In order to assess the role of CPS III in virulence a mutant in the CPS III operon was tested 
for virulence compared to wild type B. pseudomallei in the Syrian hamster model of 
melioidosis. Syrian golden hamsters were inoculated intraperitoneally with 101 to 103 cells of 
either wild-type B. pseudomallei 1026b or the capsule mutant SZ1829. After 48 h, the LD50 
values were determined. SZ1829 had LD50 values of <10 CFU, identical to that of wild type B. 
pseudomallei, indicating that this capsule is not required for virulence. In addition, the bacterial 
load in the blood of the infected hamsters was similar to that of wild-type and significantly 
higher than that of the non-pathogenic B. thailandensis E264 and the CPS I mutant, B. 
pseudomallei SR1015, both of which are incapable of establishing bacteremia [37, 50]. This 
indicates that CPS III does not contribute to persistence in the blood. Similar results were 
obtained for CPS II and CPS IV mutants, but we went on to further characterize CPS III. 
4.3. Expression of CPS III in host and environmental conditions 
A lux reporter strain was constructed in the CPS III operon by cloning an internal fragment 
of one of the genes into pGSV3-lux, a suicide vector containing a promoterless lux operon 
from Photorhabdus luminescens [53]. Regulation of this capsule in an environment similar to 
that encountered in the host was determined by growing the lux reporter strain, SZ1829, in 
the presence of M9 plus 1% glucose versus M9 plus 1% glucose plus 30% normal human 
serum (NHS). Absorbance (OD540) and luminescence (in relative light units) measurements 
were taken every hour. The expression of CPS III (SZ1829) was higher in M9 plus 1% 
glucose alone compared to M9 plus 1% glucose plus 30% NHS. The expression of SZ1829 
was 3-4 fold lower in 30% NHS. This was in contrast to the expression of CPS I (SZ211) (see 
section 3.5), which was significantly more highly expressed in 30% NHS at a level of 3-4 fold 
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compared to growth in M9 plus 1% glucose alone [55]. Although CPS III demonstrated 
higher expression initially in 30% NHS, this may have been due to the fact that the addition 
of NHS caused precipitation in the media which affected the optical density of the cultures.  
The expression of the lux operon in reporter strains SZ211 (CPS I-) and SZ1829 (CPS III-) was 
also measured in water to determine whether CPS III was induced in this environment. 
Overnight cultures of SZ211 and SZ1829 were inoculated into sterile water and incubated at 
37oC without shaking. Capsule expression was determined as described above, but the 
luminescence/absorbance calculations for water were compared to the values for these 
strains when grown in LB. CPS III was found to be induced in water compared to LB. The 
expression of SZ1829 was found to be significant with an increase of 2-3 fold over the course 
of the experiment. The expression of CPS I was found to be greater than 4 fold higher in LB 
compared to water [55].  
Microarray analysis of capsule expression was performed using a low-density DNA 
microarray. RNA was isolated from the livers and lungs of hamsters infected with B. 
pseudomallei and from B. pseudomallei grown in LB. The results of the microarray experiment 
are shown in Table 1 [55]. The level of gene expression, or fold change, is represented as the 
ratio of gene expression in the hamster compared to growth in LB. As shown in Table 1, CPS 
III genes were not found to be significantly expressed in vivo since most of the fold changes 
were determined to be less than 2-fold. Many of the genes had negative fold change values, 
indicating that these genes are suppressed in the host environment. The highest fold change 
result was 2.337866 for BPSS1827, a predicted glucose-6-phosphate isomerase, which is still 
much lower than the fold changes observed for CPS I genes, which were significantly higher 
[58]. 
 
Gene ID Predicted function Fold Change  
(in vivo vs. in vitro) 
BPSS1825 Glycosyltransferase 1.757155 
BPSS1826 Glycosyltransferase 0.093565 
BPSS1827 Glucose-6-phosphate isomerase 2.337866 
BPSS1828 Glycosyltransferase -0.66607 
BPSS1829 Glycosyltransferase -0.18061 
BPSS1830 Capsule export, tyrosine-protein kinase -0.30655 
BPSS 1831 Capsule export, outer membrane protein 0.725849 
BPSS1832  Transport, tyrosine-protein phosphatase 1.52665 
BPSS1833 UDP-glucose-6-dehydrogenase -0.71411 
BPSS1834 Sugar transferase -0.07963 
BPSS 1835 Mannose-1-phosphate guanyltransferase -0.75075 
*Note: Gene expression representative of the liver and lungs of infected hamsters. 
Table 1. Microarray analysis of B. pseudomallei CPS III expression following intraperitoneal inoculation 
in the hamster model of melioidosis. 
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4.4. Carbohydrate composition of CPS III 
Glycosyl composition analysis was performed on the purified capsule by combined gas 
chromatography/mass spectrometry (GC/MS). GC/MS results indicated that CPS III is 
composed of galactose, glucose, mannose, xylose, and rhamnose residues, with the highest 
proportion of carbohydrate being galactose and glucose. Glycosyl linkage analysis was also 
performed [55]. The predominant glycosyl residue detected was a terminally-linked 
heptopyranosyl (t-Hep) at a percentage of 23.2. Other residues detected were a terminally-
linked and a 4-linked glucopyranosyl (t-Glcp) (4-Glcp) at percentages of 14.6 and 10.8, 
respectively [55]. 
5. Conclusion 
Although significant advances have been made in the field, melioidosis continues to be a 
public health concern in many regions of the world [59]. Completion of the sequencing of 
the B. pseudomallei genome has revealed potential virulence determinants and comparative 
genomics between the genomes of B. pseudomallei, B. thailandensis, and B. mallei species has 
contributed to a better understanding of the organism. Further studies are ongoing to define 
the pathogenesis of B. pseudomallei and to identify effective vaccine candidates and 
diagnostic targets [54, 59]. 
To obtain virulence determinants unique to B. pseudomallei, we used subtractive 
hybridization between this organism and a related nonpathogenic organism, B. thailandensis. 
Analysis of the subtractive hybridization library revealed that B. pseudomallei contains a 
number of DNA sequences that are not found in B. thailandensis. One of the subtraction 
clones, pDD1015, demonstrated weak homology to a glycosyltransferase, WbpX, from P. 
aeruginosa [43]. The insert from pDD1015 was cloned into a mobilizable suicide vector for 
insertional inactivation of the glycosyltransferase gene in wild-type B. pseudomallei. The 
resulting strain, SR1015, was markedly less virulent than the parent strain in an animal 
model. We determined that SR1015 harbored a mutation in a glycosyltransferase gene 
involved in the production of a capsular polysaccharide which we subsequently designated 
as CPS I. We then identified the operon involved in the biosynthesis and transport of this 
capsular polysaccharide (CPS I) [42]. The genes identified encode for proteins that are 
similar to proteins involved in the biosynthesis and export of capsular polysaccharides, 
particularly those involved in the production of group 3 capsular polysaccharides. Group 3 
capsules include the E. coli K10 capsule and may also include the H. influenzae group b 
capsule and the capsule produced by N. meningitidis serogroup B [8]. Group 3 capsules are 
always coexpressed with O serogroups, are not thermoregulated, are transported by an ABC-2 
exporter system, and do not contain the kpsU and kpsF genes, and usually the gene clusters 
map near the serA locus [8]. Thus far, no serA locus that is associated with the type I O-PS 
cluster was identified, but this polysaccharide is coexpressed with O antigen and lacks the 
kpsU and kpsF genes, and genes encoding for a putative ABC-2 transporter have been 
identified. The genes involved in the production of group 3 capsules are organized into 
regions and are divergently transcribed. Regions 1 and 3 are generally conserved and contain 
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genes involved in export of the polysaccharide. These regions flank region 2, which contains 
the biosynthetic genes and is not conserved between serotypes [4]. The genetic organization of 
the CPS I is also similar to that of other capsule gene clusters in that the genes are organized 
into more than one transcriptional unit and appear to be divergently transcribed [42].  
The polysaccharide with the structure -3)-2-O-acetyl-6-deoxy-β-D-manno-heptopyranose-(1- 
was originally isolated and characterized as an O-PS component of LPS in B. pseudomallei 
and was designated type I O-PS [35]. However, our results suggested that this 
polysaccharide is a capsule rather than an O-PS moiety. The genes involved in the 
production of this capsule demonstrated strong homology to the genes involved in the 
production of capsular polysaccharides in many organisms, including N. meningitidis, H. 
influenzae, and E. coli. In addition, the export genes associated with this cluster are not 
associated with the previously characterized O-PS gene cluster [36]. Western blot analysis of 
proteinase K cell extracts and silver staining showed that this polysaccharide has a high 
molecular mass (200 kDa) and lacks the banding pattern seen with O-PS moieties. This 
conclusion was further supported by another group of researchers that demonstrated this 
polysaccharide is a capsule rather than an O-PS component of LPS because it lacks a lipid A 
moiety and was not capable of macrophage activation [49]. Studies by our laboratory have 
indicated that mutants in the production of the core oligosaccharide of the LPS are still 
capable of producing this polysaccharide [48]. Based on the above criteria and the genetic 
similarity to group 3 capsules, we proposed that this polysaccharide is a capsule.  
Virulence genes of a number of pathogenic bacteria are located on pathogenicity islands 
(PAIs), regions on the bacterial chromosome that are present in the genome of pathogenic 
strains but rarely present in those of nonpathogenic strains. The PAIs may range in size 
from about 30 kb to 200 kb and often differ in G+C content from the remaining bacterial 
genome; the PAIs are often associated with the carriage of many virulence genes. These 
genetic units are often flanked by direct repeats and may be associated with tRNA genes or 
insertion sequence (IS) elements at their boundaries. They may also be associated with the 
presence of mobility genes, such as IS elements, integrases, transposases, and origins of 
plasmid replication. These DNA regions are considered to be unstable in that they may be 
subject to deletion with high frequency or undergo duplications and amplifications [7]. A 
number of PAIs have been described for both gram-positive and gram-negative bacteria, 
and the application of subtraction hybridization has been used to successfully identify such 
genetic elements [7]. The subtractive hybridization that was carried out between B. 
pseudomallei and B. thailandensis led to the identification of a number of sequences that were 
found to be A-T rich compared to the rest of the B. pseudomallei chromosome. This, 
combined with the fact that insertional mutagenesis of the glycosyltransferase gene 
identified by this method resulted in an avirulent strain, suggests that we may have 
identified DNA sequences from a putative PAI and that the capsular polysaccharide gene 
cluster may be located on this island. It is possible that B. pseudomallei, B. mallei, and B. 
stabilis acquired DNA encoding for capsule as well as other potential, yet unidentified 
virulence factors by horizontal transfer recently in evolution. B. pseudomallei and B. mallei are 
known to contain IS elements that are present in B. cepacia but not in B. thailandensis [56, 60]. 
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Capsule production has been correlated with virulence in many bacteria, particularly those 
causing serious invasive infections of humans [61]. Our studies demonstrated that CPS I is 
critical for the virulence of B. pseudomallei [42, 50]. A number of functions have been 
suggested for polysaccharide capsules: prevention of desiccation for transmission and 
survival, adherence for colonization, resistance to complement-mediated phagocytosis and 
complement-mediated killing, and resistance to specific host immunity due to a poor 
antibody response to the capsule [4]. 
To establish a correlation between capsule production and clinical infection a number of B. 
pseudomallei strains isolated from clinical specimens were tested for CPS I production. All 55 
strains tested were found to produce CPS I by western blot analysis [51]. In addition 10 
strains of B. thailandensis were tested and found negative for CPS I production, confirming 
the importance of CPS I in virulence as well as clinical infection.  
CPS I production by B. pseudomallei was shown to contribute to the persistence of the 
organism in the blood of the host. All CPS I mutants tested in the animal model could not be 
isolated from the blood following infection. The addition of purified capsule was shown to 
increase the virulence of the CPS I mutant strains SR1015 and SZ210 in the animal model. 
Differences in tissue distribution between wild type B. pseudomallei and SR1015 in infected 
hamsters indicated that SR1015 was cleared from the blood because the numbers of SR1015 
in the blood of infected hamsters was 10,000-fold lower than that of wild type 1026b and 
lower than the initial inoculum of 100 cfu/ml [50]. 
CPS I production was shown to be responsible for persistence in the blood by evasion of the 
complement cascade and the mechanism for this was determined to be through the 
reduction of C3b deposition and opsonophagocytosis. The addition of purified CPS I to 
serum bactericidal assays showed that the capsule contributes to increased resistance of 
serum sensitive strains lacking the O-polysaccharide moiety (O-PS) of LPS to the 
bactericidal effects of normal human serum. However, CPS I mutants themselves were not 
found to be serum sensitive because they still produced O-PS, which was previously shown 
to be responsible for serum resistance, because it prevents lysis by the MAC complex [36]. 
This led us to postulate that CPS I was affecting the complement cascade through some 
other mechanism and it was found that this mechanism was through the reduction of C3b 
deposition and opsonization [50]. Both Western blot analysis and immunofluorescence 
microscopy experiments using a mouse monoclonal antibody to human C3b demonstrated 
the inhibition of C3b deposition by CPS I. In both experiments C3b deposition was more 
pronounced on the surface of the CPS I mutant compared to wild type. Also evident was 
that some C3b deposition occurred in the wild type, but this was expected since bacterial 
capsules are known to allow the diffusion of some C3b to the bacterial surface and B. 
pseudomallei is capable of activating the alternative pathway of complement culminating in 
the formation of the MAC complex [36, 62]. The accumulation of C3b affects the 
amplification step of the complement cascade and therefore, the less C3b deposited the less 
C5a is generated for phagocyte recruitment [63]. This explains the increased clearance of 
CPS I mutants from the blood. This conclusion was supported by the fact that B. 
thailandensis, the non-pathogenic organism which lacks CPS I, has been shown to be serum 
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resistant, but is not capable of establishing a bacteremia in the Syrian hamster model of 
acute melioidosis [36, 37, 42]. Effective opsonization of invading bacteria results in enhanced 
phagocytosis and clearance of organisms form the blood of an infected host [52]. 
Quantitative radiolabelled phagocytic assays were also performed to establish a correlation 
between opsonization of the bacteria and phagocytosis by polymorphonuclear leukocytes. 
In the presence of serum, the CPS I mutant was more readily phagocytosed than wild type 
[50]. 
The expression of CPS I in the presence of normal human serum was found to be 
significantly elevated, also confirming that this capsule contributes to survival in the host. 
The presence of CPS I enables B. pseudomallei to survive in the blood through the inhibition 
of complement factor C3b deposition and phagocytosis [50]. The presence of this capsule 
facilitates survival as well as spreading to other organs, which can explain the 
overwhelming septicemia that is common in culture-positive melioidosis patients [64]. 
Therefore CPS I production is critical to the virulence of B. pseudomallei and further research 
will enhance the development of preventative strategies for melioidosis since this 
polysaccharide is one of the components of a B. pseudomallei subunit vaccine [28, 65]. 
Sequence analysis of the genome of B. pseudomallei revealed the presence of four operons 
possibly involved in polysaccharide capsule biosynthesis. One of these operons, (CPS I), 
corresponded to the previously identified and characterized mannoheptose capsule that was 
shown to be responsible for virulence and comprises one of the currently proposed 
melioidosis and glanders subunit conjugate vaccine [28, 66, 42, 50, 67]. The CPS I capsule 
cluster is present in the genome of B. mallei as well, but the complete cluster is not found in 
the genome of B. thailandensis [56, 57, 68]. This correlates with previous studies that have 
shown that this capsule is produced by B. mallei, but not by B. thailandensis [36, 37, 42, 56].  
Three other putative capsule operons were identified by sequence analysis and all of these 
operons were found to be present in B. pseudomallei and B. thailandensis, but not B. mallei. 
Since these capsules are found in B. thailandensis and B. pseudomallei, they may be required 
for either survival in the host or in the environment; however, further studies are required 
to determine the roles of CPS II and CPS IV. 
CPS III, located on chromosome 2, was found to contain 11 genes involved in the 
biosynthesis of a polysaccharide and was shown to be present in the genomes of B. 
pseudomallei and B. thailandensis, but not B. mallei. A mutation in the CPS III cluster did not 
affect production of CPS I and so it can be concluded that this operon encodes for gene 
products responsible for the biosynthesis of a separate capsule. CPS III was not found to 
contribute to the pathogenesis of B. pseudomallei. This capsule was not shown to be highly 
expressed in vivo by microarray analysis and was not required for virulence in the animal 
model. The CPS III mutant, SZ1829, which contains a mutation in the BPSS1829 gene as a 
result of insertional inactivation, was found to be as virulent in the animal model as wild 
type B. pseudomallei. The expression of this capsule was shown to be elevated when 
incubated in water, but suppressed in the presence of normal human serum [55]. The 
presence of the CPS III cluster in B. pseudomallei and B. thailandensis, both of which can 
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survive for long periods in the environment compared to B. mallei, the increased expression 
of this capsule in water, and the low level of expression of this capsule in vivo, suggests that 
this capsule may contribute to the survival of B. pseudomallei in the environment [69].  
Previous studies have demonstrated that B. pseudomallei produces three other capsular 
polysaccharides in addition to CPS I and these have been structurally characterized. One is 
an acidic polysaccharide with the structure, -3)-2-O-acetyl-β-D-Galp-(1-4)-α-D-Galp-(1-3)-β-
D-Galp-(1-5)-β-D-KDOp-(2-, which is recognized by patient sera [32]. The other two are: a 
branched 1,4-linked glucan polymer ((CP-1a) and a triple-branched heptasaccharide 
repeating unit composed of rhamnose, mannose, galatose, glucose, and glucoronic acid (CP-
2) [49]. Combined GC/MS analysis of CPS III revealed that the composition of this capsule 
demonstrates some similarity to the composition of the previously described capsule CP-2 
composed of rhamnose, mannose, galactose, glucose, and glucoronic acid; however, the 
proportions of carbohydrate residues were not similar, and the CPS III capsule was also 
found to contain xylose and not glucoronic acid. In addition, CPS III was determined to be 
composed primarily of heptose [55]. Therefore it is evident that the capsule identified in this 
study is not one of the previously described capsule structures. Some of the previously 
characterized capsules produced by B. pseudomallei have been shown to be produced under 
unique conditions [32, 49]. Strain variation, differences in expression of the capsules, and 
discrepancies between purification strategies may also explain why a number of capsules 
have been shown to be produced by this organism. Nevertheless, the genes BPSS 1825-1835 
appear to be involved in the biosynthesis of a capsule with this composition. Further 
analysis by 2D NMR would be required to definitively establish a connection between CPS 
III and one of the other published structures. 
Studies by another laboratory have also focused on the presence of these capsule clusters in 
B. pseudomallei. Sarkar-Tyson et al. identified two polysaccharide clusters, one of which 
corresponds to the CPS III presented in this paper, but the authors identified this cluster as 
type IV O-PS (2007). The type IV O-PS was found to be involved in virulence in a mouse 
model [70]. However, a mutant in this polysaccharide did not demonstrate any difference in 
hydrophobicity compared to wild-type, indicating that this polysaccharide does not 
contribute to making the cell surface more hydrophobic, which is an advantageous 
characteristic for some pathogenic bacteria. The differences in virulence compared to the 
current work can be attributed to the use of different animal models; however, all other data 
seem to indicate that this capsule is not required for virulence. 
A study was recently published which outlines the identification of another capsule 
produced by B. pseudomallei [71]. This capsule was determined to be composed of 1,3-linked 
α-D-mannose residues. This capsular polysaccharide was also found to be produced by B. 
mallei. The genes involved in the synthesis of this polysaccharide have not yet been 
identified and work is also underway to determine the role for this novel capsule in the 
pathogenesis of melioidosis and glanders. 
B. pseudomallei is an environmental saprophyte often found in soil and stagnant water and 
incidence of the disease is high in rice farmers in Southeast Asia [22, 69]. This organism 
 
The Complex World of Polysaccharides 148 
harbors a large genome which explains its ability to survive for long periods of time in the 
environment as well exist as a significant pathogen in both humans and animals. The 
presence of multiple polysaccharide clusters in the genome and the production of multiple 
capsule structures under differing conditions may contribute to the ability of this organism 
to adapt to a variety of conditions. As demonstrated in this study, capsule expression is 
dependent on the particular environment, which indicates that B. pseudomallei produces 
these capsules to promote a survival advantage either in the host or in the environment. 
Further studies aimed at characterizing the capsules of B. pseudomallei will be beneficial to 
understand the pathogenesis of this organism and to advance further vaccine development.  
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